News Archive

Industry aTTP Patient Focus Group Opportunity

A healthcare research firm is recruiting patients from accross Canada to share their experiences with aTTP. The purpose of this focus group will be to help a particular pharmaceutical company understand the aTTP journey and the types of support from which aTTP patients can benefit. Participation should take 2 hours, and compensation will be provided for participant's time.
 

2019 Funded Grant

Answering TTP Foundation had committed almost $2 million to research grants through 2021 thanks to our grass-roots fundraising campaigns like International TTP Day. The 2019 research competition attracted research proposals from North America and Europe. Proposals were peer reviewed by other TTP researchers and physicians. The winner was selected based on scientific merit.

ISTH Invites Public Comment on Draft TTP Guidelines

The ISTH welcomes the public to comment on its draft recommendations for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) via online survey only by October 21.

Answering TTP Foundation will submit feedback reviewed by a panel of patients and supporters. Clinicians, researchers, allied health professionals, policy makers, industry representatives, patients, caregivers, and other members of the public have been invited to contribute to this process.

Industry aTTP Patient Advisory Board Opportunity

A healthcare research firm is recruiting patients to assemble an advisory board of people living with an aTTP diagnosis. This advisory board will provide insight and feedback for the benefit of a particular pharmaceutical company. Participants will be compensated at a fair market value for their time.
 
For more information and for participation instructions click here.
Support Groups

Fall 2018 Ohio TTP & aHUS Support Group Meeting

The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.

Pages